Weekly vs. Every-3-Week Paclitaxel and Carboplatin for Ovarian Cancer

Overview of attention for article published in New England Journal of Medicine, February 2016

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (99th percentile)
Good Attention Score compared to outputs of the same age and source (73rd percentile)

Mentioned by

news: 20 news outlets
blogs: 1 blog
policy: 2 policy sources
twitter: 55 X users

facebook: 2 Facebook pages
wikipedia: 1 Wikipedia page
googleplus: 2 Google+ users
guideline: 8 clinical guideline sources

Readers on

mendeley: 323 Mendeley

So far, Altmetric has seen 58 X posts from 55 X users, with an upper bound of 1,139,563 followers.

Sutter Health Dr. John Chan NEJM: Weekly vs. Every-3-Week Paclitaxel & Carboplatin for Ovarian Cancer. PubMed NCBI https://t.co/2AJRp8zljp

Weekly paclitaxel, vs. paclitaxel admin every 3 weeks, did not prolong PFS in ovarian cancer who received Avastin. https://t.co/p4rBzs8hKT

Weekly vs. Every-3-Week Paclitaxel and Carboplatin for Ovarian Cancer. https://t.co/MNxmDM5M3Y

RT @NEJM: Weekly paclitaxel, compared w every 3 wks, doesn‘t prolong progression-free survival among patients w ovarian cancer https://t.co…

This page shows the most recent X posts that mention this research output. Click here to find out how to access more activity, including 54 additional X posts.